Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by LakeOromoctoon Jun 01, 2023 2:08am
204 Views
Post# 35474198

Info I found from Linda pullan on negotiating.

Info I found from Linda pullan on negotiating.

4 to 1

  • 4 term sheets are worked on for every deal signed, according to a Syneos survey of deal makers.  
  • Differences in perception of value is the #1 reason for failure. 

 

So how to minimize the differences in value perception?

 

 

Deal Prep: work to understand how partner will see development, risks, competition and differentiation. Have a clear path to potential and risk reduction. 

 

Build confidence:  Share new data, offer an MTA, offer experts, lots of communication! 

 

Diligence: easy to miss things in diligence in new area – ask their assumptions, development plans.  Give a guided tour of the data room.  Get experts together. 

 

Negotiations: Share valuation modeling assumptions, share experts outside the company

 

Don't fix the price before defining the deal.  This can create a value disconnect.  

 

<< Previous
Bullboard Posts
Next >>